Provided is a method for the selective differentiation into M1 macrophages under a pressurized environment, and more particularly, a method for the selective differentiation of undifferentiated macrophages into M1 macrophages, the method including incubating the undifferentiated macrophages in an incubator under the pressurized environment. In addition, provided is a method for producing osteoclasts, the method including: incubating undifferentiated macrophages in an incubator under a pressurized environment to differentiate into M1 macrophages; and differentiating the differentiated M1 macrophages into osteoclasts.

The present disclosure provides a crosslinking agent, the preparation process and uses thereof, a hydrogel and a biodegradable cryogel including the crosslinking agent.

Compositions and methods for transferring a nucleic acid to a target cell using an immune system cell are provided.

The disclosure provides a method of new use of an immunomodulatory drug comprising a water-soluble acidic peptidoglycan from sprouts of the plant Solanum tuberosum (WSPG) for prevention and treatment of metastatic tumor growth, comprising an application of a therapeutically effective dose of a said immunomodulatory drug or a pharmaceutical composition of a said immunomodulatory drug with a pharmaceutically acceptable carrier or excipient, or a pharmaceutically effective amount of mammalian immune cells treated with said immunomodulatory drug WSPG in vitro/ex vivo to a patient in need thereof.

The present invention relates to methods for deriving human hematopoietic progenitors, primitive macrophages, and microglial cells from human pluripotent stem cells. In particular, provided herein are highly efficient and reproducible methods of obtaining human primitive macrophages and microglia from human pluripotent stem cells, where the primitive macrophages and microglia can be suitable for clinically relevant therapeutic applications.

The present invention includes methods and compositions for treating cancer, whether a solid tumor or a hematologic malignancy. By expressing a chimeric antigen receptor in a monocyte, macrophage or dendritic cell, the modified cell is recruited to the tumor microenvironment where it acts as a potent immune effector by infiltrating the tumor and killing the target cells. One aspect includes a modified cell and pharmaceutical compositions comprising the modified cell for adoptive cell therapy and treating a disease or condition associated with immunosuppression.

The present invention is directed to methods of inducing a phenotypic change in a population of monocytes and; or macrophages. The method includes administering to the population of monocytes and/or macrophages, a macrophage stimulating agent coupled to a carrier molecule, wherein the carrier molecule facilitates macropinocytic uptake of the agent by monocytes and macrophages in the population and is defective in neonatal Fc receptor binding, wherein the administering induces a phenotypic change in the monocytes and macrophages in the population.

Cell populations, compositions, and methods are provided relating to target priming of macrophage cells. The macrophages, once primed or activated with a microorganism, can be used to prevent or treat infection by the microorganism. Likewise, once primed or activated by a tumor cell or tumor antigen, the macrophage cell can be used to prevent or treat tumor of the same kind. The priming can be carried out in vitro or ex vivo. The macrophages can be isolated from the subject of disease prevention or treatment.

Provided is a method for modifying a chimeric antigen receptor-modified T cell (CAR-T cell). The method comprises expressing an ScFv-CD8-4-1 BB-CD3ζ molecule in a T cell. The CAR-T cell prepared using the method can specifically recognize and bind to a tumor cell with elevated expression of a ROBO1 protein, and can be used to prevent and treat a corresponding tumor-related disease

A conditioned medium of CD11b.sup.low macrophages and methods for preparing it are provided. Pharmaceutical compositions comprising the CD11b.sup.low macrophages conditioned medium or a culture of CD11b.sup.low macrophages and their use in the treatment of cancer or fibrosis are also provided.